Illumina, Inc. (NASDAQ:ILMN) Holdings Lifted by Hardman Johnston Global Advisors LLC

Hardman Johnston Global Advisors LLC increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 157.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 167,959 shares of the life sciences company’s stock after buying an additional 102,688 shares during the quarter. Hardman Johnston Global Advisors LLC’s holdings in Illumina were worth $22,444,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of ILMN. WCM Investment Management LLC grew its holdings in shares of Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after buying an additional 867,673 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Illumina by 148.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after purchasing an additional 631,294 shares in the last quarter. Janus Henderson Group PLC grew its stake in Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after purchasing an additional 625,245 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in Illumina by 116.9% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company’s stock valued at $115,663,000 after purchasing an additional 466,519 shares in the last quarter. Finally, Iron Triangle Partners LP purchased a new position in Illumina in the third quarter valued at about $57,380,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 3.1 %

Shares of ILMN opened at $94.20 on Monday. The firm has a market capitalization of $14.92 billion, a price-to-earnings ratio of -12.27, a PEG ratio of 1.60 and a beta of 1.10. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The business’s fifty day moving average price is $127.98 and its two-hundred day moving average price is $134.22. Illumina, Inc. has a 52 week low of $93.50 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Canaccord Genuity Group lowered their target price on Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Friday, February 7th. Royal Bank of Canada decreased their price target on Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Piper Sandler upped their price target on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Robert W. Baird upped their price target on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Finally, Citigroup downgraded Illumina from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.